In addition, the development of a new v1-specific anti-ROR1 Ab for IHC should reduce the amount of ROR1 tumour staining, which may impact it prevalence in MCL, DLBCL and FL by reducing the values shown at this point. This evidence concerns the gene ROR1 and diffuse large B-cell lymphoma.